Type
Genetic Testing
Duration
15 min
Sample
Blood (maternal venous)
What's included
5 deliverables in this treatment
- Maternal venous blood draw at the laboratory
- Analysis of cell-free fetal DNA for trisomy 21, 18 and 13
- Optional fetal sex determination and expanded aneuploidy panels
- Written laboratory result report
- Referral pathway for confirmatory diagnostics if a result is high-risk
CAPART (Czech Accurate Prenatal Aneuploidy Rapid Test) is a non-invasive prenatal test that analyses fetal DNA circulating in a maternal blood sample to screen for the most common chromosomal trisomies, including trisomy 21 (Down syndrome), 18 and 13. Introduced by the laboratory in 2026, it requires only a routine blood draw from the mother and carries none of the miscarriage risk associated with invasive sampling. Expanded variants add sex chromosome assessment and broader aneuploidy panels. The test is suitable from early in the second trimester and is offered to self-paying patients who want reassurance beyond standard ultrasound screening.
About this treatment
Non-invasive prenatal testing (NIPT) works by analysing cell-free fetal DNA fragments that pass into the mother's bloodstream from the placenta. A standard venous blood sample is taken from the mother and the fetal DNA fraction is sequenced and analysed to assess the likelihood of common chromosomal aneuploidies. Because no needle enters the uterus, the test avoids the small miscarriage risk associated with amniocentesis or chorionic villus sampling,…
The laboratory's CAPART platform screens for the principal autosomal trisomies — trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). Several panel levels are available: the base CAPART test, CAPART including fetal sex determination, and broader Trisomy panels (Trisomy test, Trisomy XY, Trisomy+, and Trisomy test complete) that extend the analysis to sex chromosome aneuploidies and additional findings. Patients choose…
NIPT is a screening rather than a diagnostic test: a high-risk result is normally confirmed by an invasive diagnostic procedure such as amniocentesis with karyotyping. The laboratory, which sits directly above a centre for prenatal diagnosis, can arrange this confirmatory pathway. The test is best suited to expectant parents who want a low-risk, early, and sensitive screen for chromosomal conditions.
Good to know
- Sample
- Maternal blood draw (non-invasive)
- Screens for
- Trisomy 21, 18, 13 (+ sex chromosomes on expanded panels)
- Panel levels
- CAPART base through Trisomy test complete
- Risk
- No miscarriage risk (no invasive sampling)
Who is this for?
Expectant parents seeking early, low-risk chromosomal screening; higher-maternal-age pregnancies; reassurance after uncertain ultrasound findings
About the clinic
Reviews, team and credentials
Independent review links and clinic-reported team information.
Clinical team
The laboratory is headed by RNDr. Jitka Kadlecová, Ph.D., supported by a team of cytogenetic and molecular genetic specialists with long-term laboratory experience in prenatal and postnatal genetic diagnostics.
Languages: Czech, English
Treatment highlights
- Maternal venous blood draw at the laboratory
- Analysis of cell-free fetal DNA for trisomy 21, 18 and 13
+3 more items in What's included
From 9,000 Kč for the CAPART non-invasive prenatal test (base panel). CAPART including fetal sex is 9,500 Kč. Expanded panels: Trisomy test 11,000 Kč; Trisomy XY 11,500 Kč; Trisomy+ 12,500 Kč; Trisomy test complete 13,500 Kč. Price covers the maternal blood draw and laboratory analysis.